Xencor, Inc OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
Xencor, Inc (XNCR) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of -$2.24 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2026-02-25
- Xencor, Inc oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2025 was -$2.24M, a 214.59% decline from fiscal 2024.
- Xencor, Inc oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2024 was $1.95M.
- Xencor, Inc oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2023 was -$8.24M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|
| 2025-12-31 | -$2.24M 10-K · filed 2026-02-25 |
| 2024-12-31 | $1.95M 10-K · filed 2026-02-25 |
| 2023-12-31 | -$8.24M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |